Product Information
DABIGATRAN ETEXILATE 110 MG CP is a generic product labeled by Dr. Reddy's Laboratories Inc., priced at $0.9198 per EA under NDC 43598045360. Its NADAC has been published 67 times since Mar 19, 2025.
Strength
110 mg/1
Manufacturer
Dr. Reddy's Laboratories Inc.NDC
43598045360
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
DABIGATRAN ETEXILATE MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA208048On Market Since
2/28/2025
Pharmacological Classes
Price Statistics
The NADAC for DABIGATRAN ETEXILATE 110 MG CP has been published 67 times since Mar 19, 2025, and over the history we have for it it has declined 53.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9198 per EA |
|---|---|
| All-time high | $1.9786 (Apr 16, 2025) |
| All-time low | $0.9196 (May 20, 2026) |
| 52-week high | $1.8725 |
| 52-week low | $0.9196 |
| Median price | $1.7206 |
| Average price | $1.5370 |
| Largest weekly change | -12.4% (Dec 17, 2025) |
| Weeks tracked | 67 |
| Tracking since | Mar 19, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the Dabigatran etexilate market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of DABIGATRAN ETEXILATE 110 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 110 MG CP, manufactured by Dr. Reddy's Laboratories Inc., is $0.9198 per EA (NDC 43598045360), effective Jun 24, 2026.
How has the price of DABIGATRAN ETEXILATE 110 MG CP changed over time?
Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has declined 53.5%. It has been tracked across 67 weekly CMS publications since Mar 19, 2025.
What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 110 MG CP?
Since Mar 19, 2025, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has ranged from a low of $0.9196 (May 20, 2026) to a high of $1.9786 (Apr 16, 2025), with a median of $1.7206 per EA.
Are there cheaper alternatives to DABIGATRAN ETEXILATE 110 MG CP?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of DABIGATRAN ETEXILATE 110 MG CP, so no direct lower-cost alternative is listed.
Who manufactures DABIGATRAN ETEXILATE 110 MG CP?
DABIGATRAN ETEXILATE 110 MG CP (NDC 43598045360) is labeled by Dr. Reddy's Laboratories Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification